摘要
脑膜转移是晚期非小细胞肺癌(NSCLC)患者中相对少见的并发症。由于脑膜转移的诊断及监测困难,缺少系统且特异性的治疗方案,患者预后较差。NSCLC脑膜转移的治疗包括化疗、放疗、鞘内注射治疗、靶向治疗及免疫治疗等。其中全身化疗及放疗的疗效并未取得共识,随着表皮生长因子受体-酪氨酸激酶抑制剂研究的进展,脑膜转移患者生存期得到明显的提升。此外,由于鞘内注射治疗直接通过腰椎穿刺注入化疗药物,可以达到高浓度的脑脊液药物浓度,从而获得良好的治疗效果。
Leptomeningeal metastasis is a relatively rare complication in patients with advanced non-small cell lung cancer(NSCLC).Due to the difficulty in diagnosing and monitoring meningeal metastases,and the lack of a systematic and specific treatment plan,the prognosis of these patients is poor.The treatment of leptomeningeal metastasis in NSCLC mainly includes systemic chemotherapy,radiation therapy,intrathecal injection therapy,targeted therapy and immunotherapy.Although there is no consensus on the efficacy of systemic chemotherapy and radiation therapy,with the advances in the research on the new epidermal growth factor receptor-tyrosine kinase inhibitors,the survival of the patients with leptomeningeal metastasis has been greatly improved.In addition,due to the directness of intrathecal injection of chemotherapy drugs through lumbar puncture,high cerebrospinal fluid drug concentrations can be achieved to obtain good therapeutic effects.
作者
赵邱煜
信涛
ZHAO Qiuyu;XIN Tao(DivisionⅡof Medical Oncology,the Second Affiliated Hospital of Harbin Medical University,Harbin 150080,China)
出处
《医学综述》
2021年第2期303-307,共5页
Medical Recapitulate
关键词
非小细胞肺癌
脑膜转移
表皮生长因子受体-酪氨酸激酶抑制剂
神经系统转移
Non-small cell lung cancer
Leptomeningeal metastasis
Epidermal growth factor receptor-tyrosine kinase inhibitors
Nervous system metastasis
